Langerhans cell histiocytosis
Conditions
Interventions
SS:First-line treatment
MS RO-:First-line and second-line treatment
MS RO+:Second-line treatment and remedial treatment
Sponsors
Beijing Children's Hospital, Capital Medical University, National Children's Medical Center
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients were diagnosed as LCH by pathological examination; 2. Patients aged <=18 years; 3. Patients were not received any anti-tumor treatment before diagnosis; 4. Informed consent were obtained from guardians of the patients and the patients (more than 8 years old).
Exclusion criteria
Exclusion criteria: 1. Patients who have been treated with any anti-tumor treatment before enrollment; 2. Patients who can't carry out systematic treatment according to the standardized diagnosis and treatment protocol; 3. Patients who can't carry out the treatment according to the established protocol due to personal reasons during the treatment; 4. Those who have any significant abnormal coexisting diseases or mental diseases that affect the life safety and compliance of patients, and informed consent, research participation, follow-up or result interpretation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free Survival;Cumulative incidence of relapse;Cumulative incidence of permanent consequences;Hazard ratio; | — |
Countries
China
Contacts
Public ContactRui Zhang
Beijing Children's Hospital, Capital Medical University, National Children's Medical Center
Outcome results
None listed